Lower sales of Tysabri predicted
It is expected that fewer patients will be taking Tysabri, used to treat multiple sclerosis, as two more patients have been diagnosed with a potentially fatal brain disease. Financial analysts predict that the drug will have only about 75,000 users by 2013, which is below Biogen Idec Inc.'s goal of 100,000.
- Will More Pioneer ACOs Defect?
- Charity HealthCare Conundrum Brewing Among Providers
- MU Final Rule Disappoints Some CIOs
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- Interventional Radiology No Longer a Sub-Specialty
- 'Terrible' Patient Becomes Dedicated Nurse
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- CNO Leads $1M Charge for New Scrubs, Uniforms
- mHealth Tackles Readmissions
- Acute Kidney Injury Gets New Focus